Eagle Global Advisors LLC Boosts Stake in Haleon PLC Sponsored ADR $HLN

Eagle Global Advisors LLC raised its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 28.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 318,000 shares of the company’s stock after purchasing an additional 70,000 shares during the quarter. Eagle Global Advisors LLC’s holdings in Haleon were worth $3,215,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HLN. Bank of America Corp DE raised its position in Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the period. Optiver Holding B.V. purchased a new stake in shares of Haleon in the 3rd quarter valued at $45,593,000. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after buying an additional 3,207,986 shares during the period. ABC Arbitrage SA raised its holdings in shares of Haleon by 159.4% in the 3rd quarter. ABC Arbitrage SA now owns 2,727,350 shares of the company’s stock valued at $24,464,000 after buying an additional 1,675,889 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in shares of Haleon by 3,548.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock valued at $17,473,000 after buying an additional 1,638,784 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on HLN. Argus upgraded Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft downgraded Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Finally, HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Haleon has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Trading Down 1.6%

HLN opened at $9.53 on Wednesday. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The stock has a market capitalization of $42.46 billion, a price-to-earnings ratio of 24.42, a PEG ratio of 2.05 and a beta of 0.26. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The business has a fifty day moving average price of $10.30 and a 200 day moving average price of $9.96.

Haleon (NYSE:HLN) last released its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion for the quarter. Sell-side analysts expect that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current fiscal year.

Haleon Announces Dividend

The business also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be paid a dividend of $0.1307 per share. This represents a yield of 266.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s payout ratio is presently 64.10%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.